Viyash Scientific Ltd

Premier Energies Ltd, Tanla Platforms Ltd, Jana Small Finance Bank Ltd and Varun Beverages Ltd are among the other losers in the BSE's 'A' group today, 26 August 2026.Viyash Scientific Ltd crashed 5.43% to Rs 263.1 at 14:48 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 103.44 lakh shares were traded on the counter so far as against the average daily volumes of 1.97 lakh shares in the past one month.Premier Energies Ltd lost 4.42% to Rs 985.55. The stock was the second biggest loser in 'A' group.On the BSE, 2.01 lakh shares were traded on the counter so far as against the average daily volumes of 55227 shares in the past one month.Tanla Platforms Ltd tumbled 3.98% to Rs 533.5. The stock was the third biggest loser in 'A' group.On the BSE, 51587 shares were traded on the counter so far as against the average daily volumes of 50078 shares in the past one month.Jana Small Finance Bank Ltd fell 3.94% to Rs 547.55. The stock was the fourth biggest loser in 'A' group.On the BSE, 82855 shares were traded on the counter so far as against the average daily volumes of 1.22 lakh shares in the past one month.Varun Beverages Ltd shed 3.68% to Rs 421.9. The stock was the fifth biggest loser in 'A' group.On the BSE, 9.44 lakh shares were traded on the counter so far as against the average daily volumes of 4.5 lakh shares in the past one month.

Viyash Scientific Ltd share price softened by 1.19% to Rs 273.8. The Company's net profit rose by 19.45% to Rs 79.29 crore, while revenue from operations slightly gained 2.87% to Rs 946.36 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.56 lakh crore, gaining 4.63%. It has improved by 0.56% over last one week and heading higher by 13.27% in last one month while the market capitalization of Viyash Scientific Ltd has inched up 2.76% and 21.93% in the same period respectively. Profit before tax (PBT) of Viyash Scientific Ltd stood at Rs 112.41 crore in Q2 FY26, expanding by 132.54% year-on-year, and dropping 10.24% quarter-on-quarter. EBITDA came in at Rs 170 crore, rallying 51.94% YoY and easing 1.03% sequentially. Total expenses posted a minor rise of 4.22% to Rs 829.75 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 402.34 crore, going up by 10.56% YoY, while employee benefits expense was at Rs 162.65 crore, rising by 8.56% YoY. For the TTM ended FY26, revenue from operations grew 13.75% to Rs 3420.31 crore, while net profit surged by 1324.54% to Rs 224.65 crore, compared to previous TTM. EBITDA jumped by 34797% to Rs 608.98 crore, and PBT jumped 2548.10% to Rs 349.02 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 322.91 crore in FY26, as against Rs 344.8 crore in FY25. Viyash Scientific Ltd soared by 54.86% in last one year, significantly outperforming the benchmark BSE Sensex which has softened by 2.56% during the same period.

Viyash Scientific Limited, formerly known as Sequent Scientific Limited, will hold a board meeting on Tuesday, August 11, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, according to a regulatory filing. The trading window for the company's securities remains closed from July 1, 2026, until August 13, 2026, in accordance with insider trading regulations.

Viyash Scientific Limited, formerly Sequent Scientific Limited, announced that its Nomination and Remuneration Committee approved the allotment of 20,01,336 equity shares of Rs 2 each, fully paid, to eligible optionees at an exercise price of Rs 86 per share under the SeQuent ESOP 2020, increasing the company’s issued and paid-up equity share capital from Rs 87,37,50,954 consisting of 43,68,75,477 equity shares to Rs 87,77,53,626 consisting of 43,88,76,813 equity shares.

Viyash Scientific announced that the 41th Annual General Meeting(AGM) of the company will be held on 11 August 2026.

Viyash Scientific (Viyash), through its wholly owned subsidiary Alivira Animal Health (Alivira), has signed a binding agreement to acquire 100% stake in BioForLife Italia S.r.l. (BFL), a leading pet care company based in Milan, Italy. The acquisition, for a cash consideration of Rs 188 crore is expected to close in Q2 FY27. The transaction represents a significant step in Viyash's strategy to capitalize on the mega-trend of a growing Companion Animal Health Generics market. It expands Alivira's global Companion Animal Health business and strengthens its presence in the European pet care market.

The acquisition, valued at approximately Rs 188 crore in cash, is expected to be completed in the second quarter of FY27. The transaction marks a significant step in Viyash Scientific's strategy to capitalize on the rapidly growing global companion animal health generics market. It is expected to strengthen Alivira's position in the European pet care sector and expand its global companion animal health business. According to the company, Italy ranks among the five largest animal health markets in Europe, with companion animal care emerging as the fastest-growing segment. Growth is being driven by increasing pet ownership, rising pet humanization trends, and higher spending on preventive and specialized veterinary care. BioForLife specializes in the development, commercialization, and distribution of pet care products. The company has built a strong presence in nutritional supplements, pharmaceuticals, and rapid diagnostic tests, while also expanding into high-growth segments such as dermatology and ophthalmology. Through its established sales network, BioForLife serves more than 80% of veterinary clinics across Italy. The acquisition is expected to provide a platform for launching new products from Alivira's pipeline in Italy, while simultaneously providing opportunities to expand the BFL range to other markets in the Alivira group located in Europe, Middle East, Asia and Latam. Dr. Haribabu Bodeputi, Managing Director and Group CEO, Viyash Scientific, said, This acquisition represents another important step in our strategy to build a leading global companion animal health business. BioForLife provides us with an established platform in Italy, one of Europe's most attractive pet care markets, while strengthening our presence across the region. The combination of BioForLife's commercial reach and Alivira's product development capabilities creates a compelling opportunity to accelerate growth, expand our companion animal portfolio and deliver greater value to veterinarians, pet owners and partners across markets. We also see meaningful opportunities to introduce innovative products into India and other geographies through our global reach. This investment reflects our continued commitment to sustainable growth, strategic expansion and long-term value creation. Sequent Scientific p is mainly engaged in the business of veterinary healthcare. The company's consolidated net profit surged 459.1% year on year to Rs 52.11 crore, while revenue from operations jumped 129% to Rs 919.96 crore in Q4 FY26 from Q4 FY25. Powered by Capital Market - Live

Net profit of Viyash Scientific rose 459.12% to Rs 52.11 crore in the quarter ended March 2026 as against Rs 9.32 crore during the previous quarter ended March 2025. Sales rose 129.02% to Rs 919.96 crore in the quarter ended March 2026 as against Rs 401.70 crore during the previous quarter ended March 2025. For the full year,net profit rose 663.48% to Rs 177.28 crore in the year ended March 2026 as against Rs 23.22 crore during the previous year ended March 2025. Sales rose 13.75% to Rs 3420.31 crore in the year ended March 2026 as against Rs 3006.84 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales919.96401.70 129 3420.313006.84 14 OPM %20.0311.51 -19.0812.87 - PBDT185.6532.77 467 626.87333.45 88 PBT125.2416.65 652 393.2394.74 315 NP52.119.32 459 177.2823.22 663 Powered by Capital Market - Live

Viyash Scientific will hold a meeting of the Board of Directors of the Company on 19 May 2026.

Net profit of Viyash Scientific declined 13.83% to Rs 38.44 crore in the quarter ended December 2025 as against Rs 44.61 crore during the previous quarter ended December 2024. Sales rose 10.90% to Rs 858.41 crore in the quarter ended December 2025 as against Rs 774.03 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales858.41774.03 11 OPM %20.4612.89 - PBDT172.8685.76 102 PBT114.3327.37 318 NP38.4444.61 -14 Powered by Capital Market - Live